How Patient-Centered Technologies Can Elevate Diabetes Clinical Trials To Align With Current Standards Of Care

Over the years, diabetes clinical trials have faced difficulties in keeping up with clinical care due to regulatory and logistical hurdles in incorporating Continuous Glucose Monitoring (CGM) devices into the trial setting. However, with recent FDA clearance of commercially available CGM devices, there has been an increasing adoption of these devices in clinical trials, at least within the United States. Nevertheless, global trials still pose challenges.

In this webinar, a panel of clinical experts specializing in diabetes care and clinical trial technology delve into the reasons behind the lag in clinical trials compared to current standards of care. Speakers on the panel include:

• C. Michael Gibson, M.S., M.D., Moderator; CEO, Baim Institute for Clinical Research; Professor of Medicine, Harvard Medical School, Interventional Cardiologist, Beth Israel Deaconess Medical Center;
• Jonathan Goldman, M.D., CEO, Clinical ink;
• Christian Born Djurhuus, M.D., PhD, BSc, Owner, Djurhuus Consulting;
• Neil Newman, Senior Director - Diabetes Therapeutic Area Architect Clinical Development, Eli Lilly; and
• Mona Khalid, VP, Value Demonstration, Health Economics and Patient Access, Endpoint Health Inc.

Access the webinar below to watch as panelists draw from their own experiences and examples of how to overcome these challenges by leveraging patient-centered technologies, innovative study designs, and taking regulatory factors into account.